Retsina Meyer, PhD, leverages her background in neuroscience, endocrinology, and business strategy to advance the field of personalized medicine in neurological disorders. Notably, Dr. Meyer founded Resilience Therapeutics, a drug development company advancing disease-modifying therapeutics for PTSD. With a successful strategic sale, Resilience advanced a novel therapeutic with measurable biomarkers into the clinic. Dr. Meyer recently served as Project Lead for a national initiative to roadmap the path forward for precision medicine in trauma-related brain disorders. The ensuing deliverables will serve the field to guide research, development, and funding for diagnostics and therapeutics. Retsina served as a Fulbright Scholar at the Norwegian Institute of Technology Center for the Biology of Memory with the Moser Lab (2014 Nobel Prize Winners); earned a PhD in Systems Neuroscience and Neuroendocrinology from MIT; and Bachelor’s Degrees in Applied Mathematics, Biochemistry and Molecular Biophysics, and Biological Psychology from the University of Arizona Honors College.